ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

SusanGalbraith,AstraZeneca’sheadofcancerresearchanddevelopment,speaksataSTATeventin2023.MarieMillerf AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev




focus

author：Wikipedia    Page View：3
Darron Cummings/AP

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

advertisement

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： US judge blocks portions of new Florida elections law
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban